Home > Rheumatology > ACR 2019 > Reproductive Issues in Rheumatic Disease > TNFi for RA during pregnancy – to stop or not to stop?

TNFi for RA during pregnancy – to stop or not to stop?

Presented By
Dr Isabell Haase, Heinrich-Heine University Düsseldorf, Germany
Conference
ACR 2019
Discontinuing TNF inhibitors (TNFi) when conceiving bares the risk of flares and higher need for steroids during pregnancy. If the mothers choose to maintain TNFi therapy, it may be safe to expand injection intervals when in remission [1]. Although there is a chance of amelioration of rheumatoid arthritis (RA) during pregnancy, many women face disease activation and flares when childbearing [2]. Disease management decisions during this time not only have to take potential harm of therapy into account but also potential risks of flares and disease activation [1]. Already prior to conception, a growing rate of future mothers are treated with TNFi. Dr Isabell Haase (Heinrich-Heine University Düsseldorf, Germany) and her fellow researchers conducted a prospective observational study to investigate the effects of continuing, stopping, or reducing TNFi therapy during pregnancy. Data was collected for clinical findings, Disease Activity Score 28/C-reactive...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on